{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T01:37:32Z","timestamp":1769823452698,"version":"3.49.0"},"reference-count":46,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CPT Pharmacom &amp; Syst Pharma"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ibrutinib is a Bruton tyrosine kinase (Btk) inhibitor for treating chronic lymphocytic leukemia (CLL). It has also been associated with hypertension. The optimal dosing schedule for mitigating this adverse effect is currently under discussion. A quantification of relationships between systemic ibrutinib exposure and efficacy (i.e., leukocyte count and sum of the product of perpendicular diameters [SPD] of lymph nodes) and hypertension toxicity (i.e., blood pressure), and their association with overall survival is needed. Here, we present a semi\u2010mechanistic pharmacokinetic\u2010pharmacodynamic modeling framework to characterize such relationships and facilitate dose optimization. Data from a phase Ib\/II study were used, including ibrutinib plasma concentrations to derive daily 0\u201324\u2010h area under the concentration\u2010time curve, leukocyte count, SPD, survival, and blood pressure measurements. A nonlinear mixed effects modeling approach was applied, considering ibrutinib's pharmacological action and CLL cell dynamics. The final framework included (i) an integrated model for SPD and leukocytes consisting of four CLL cell subpopulations with ibrutinib inhibiting phosphorylated Btk production, (ii) a turnover model in which ibrutinib stimulates an increase in blood pressure, and (iii) a competing risk model for dropout and death. Simulations predicted that the approved dosing schedule had a slightly higher efficacy (24\u2010month, progression\u2010free survival [PFS] 98%) than de\u2010escalation schedules (24\u2010month, average PFS\u2009\u2248\u200997%); the latter had, on average, \u224820% lower proportions of patients with hypertension. The developed modeling framework offers an improved understanding of the relationships among ibrutinib exposure, efficacy and toxicity biomarkers. This framework can serve as a platform to assess dosing schedules in a biologically plausible manner.<\/jats:p>","DOI":"10.1002\/psp4.13010","type":"journal-article","created":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T08:34:43Z","timestamp":1689410083000},"page":"1305-1318","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic\u2010pharmacodynamic models"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9282-9136","authenticated-orcid":false,"given":"Eman I. K.","family":"Ibrahim","sequence":"first","affiliation":[{"name":"Department of Pharmacy Uppsala University  Uppsala Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1258-8297","authenticated-orcid":false,"given":"Mats O.","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Uppsala University  Uppsala Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2979-679X","authenticated-orcid":false,"given":"Lena E.","family":"Friberg","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Uppsala University  Uppsala Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp140760"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000840"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.129"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1554862"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0964"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14540"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-362624"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.316"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89904"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-527853"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2856"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00693"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-860593"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13119"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-606038"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2617-3"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.5586.5586"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-452607"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2011.00360"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.62"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2006.048371"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25292"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.37.5.1199"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.101378"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1512710"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.787"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph14020162"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3505"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-554220"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-719294"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1409362111"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00894"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00429-z"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2021-319110"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.5045\/br.2020.S012"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-458265"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-810044"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-051458"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01063-7"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2189"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.122"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.48"}],"container-title":["CPT: Pharmacometrics &amp; Systems Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.13010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T16:47:37Z","timestamp":1695142057000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/psp4.13010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1002\/psp4.13010"],"URL":"https:\/\/doi.org\/10.1002\/psp4.13010","archive":["Portico"],"relation":{},"ISSN":["2163-8306","2163-8306"],"issn-type":[{"value":"2163-8306","type":"print"},{"value":"2163-8306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]},"assertion":[{"value":"2023-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}